Could a Once-Daily pill prevent deadly clots in cancer patients?
NCT ID NCT07005024
First seen Jun 24, 2026 · Last updated Jun 27, 2026 · Updated 1 time
Summary
This study compares two different dosing schedules of the blood thinner apixaban (Eliquis) against no blood thinner in about 996 cancer patients at moderate risk for blood clots. Participants take either 2.5 mg twice daily, 5 mg once daily, or no anticoagulant for 6 months. The goal is to see if a simpler once-daily dose is as safe and effective as the standard twice-daily dose at preventing clots and reducing deaths.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
Active substance
Apixaban (Eliquis), a blood thinner
What this could lead to
If successful, this could provide a simpler, once-daily blood thinner option to prevent dangerous clots in cancer patients, potentially reducing deaths and hospitalizations.
What could go wrong
This is a Phase 3 trial, but it's still testing a new dosing schedule. The once-daily dose may not work as well as the standard twice-daily dose, and any blood thinner carries a risk of serious bleeding.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for LYMPHOMA are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Study contacts
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
Locations
-
University of Vermont Medical Center
RECRUITINGBurlington, Vermont, 05401, United States
Contact Phone: •••-•••-•••• Email: •••••@•••••